Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

OBJECTIVE The Working Group on Civilian Biodefense has developed consensus-based recommendations for measures to be taken by medical and public health professionals following the use of plague as a biological weapon against a civilian population. PARTICIPANTS The working group included 25 representatives from major academic medical centers and research, government, military, public health, and emergency management institutions and agencies. EVIDENCE MEDLINE databases were searched from January 1966 to June 1998 for the Medical Subject Headings plague, Yersinia pestis, biological weapon, biological terrorism, biological warfare, and biowarfare. Review of the bibliographies of the references identified by this search led to subsequent identification of relevant references published prior to 1966. In addition, participants identified other unpublished references and sources. Additional MEDLINE searches were conducted through January 2000. CONSENSUS PROCESS The first draft of the consensus statement was a synthesis of information obtained in the formal evidence-gathering process. The working group was convened to review drafts of the document in October 1998 and May 1999. The final statement incorporates all relevant evidence obtained by the literature search in conjunction with final consensus recommendations supported by all working group members. CONCLUSIONS An aerosolized plague weapon could cause fever, cough, chest pain, and hemoptysis with signs consistent with severe pneumonia 1 to 6 days after exposure. Rapid evolution of disease would occur in the 2 to 4 days after symptom onset and would lead to septic shock with high mortality without early treatment. Early treatment and prophylaxis with streptomycin or gentamicin or the tetracycline or fluoroquinolone classes of antimicrobials would be advised.

[1]  S. Chanteau,et al.  Epidemiological and diagnostic aspects of the outbreak of pneumonic plague in Madagascar , 2000, The Lancet.

[2]  G. Pugliese,et al.  Anthrax as a Biological Weapon: Medical and Public Health Management , 1999, Infection Control & Hospital Epidemiology.

[3]  Philip K. Russell,et al.  Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. , 1999, JAMA.

[4]  Biological Terrorism Incidents.  Chemical and Biological Terrorism: Research and Development to Improve Civilian Medical Response , 1999 .

[5]  Henry Wilde,et al.  Medical Aspects of Chemical and Biological Warfare , 1998 .

[6]  D. Vlahov,et al.  Tuberculosis risk in funeral home employees. , 1998, Journal of occupational and environmental medicine.

[7]  J. Ezzell,et al.  Antibiotic Treatment of Experimental Pneumonic Plague in Mice , 1998, Antimicrobial Agents and Chemotherapy.

[8]  R. Titball,et al.  Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection. , 1998, The Journal of antimicrobial chemotherapy.

[9]  I. V. Ryzhko,et al.  [Characteristics of etiotropic therapy of plaque infection induced by atypical strains of F1- phenotype plaque microbe]. , 1998, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic].

[10]  S. Chanteau,et al.  Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. , 1997, The New England journal of medicine.

[11]  A. Czeizel,et al.  Teratogenic Study of Doxycycline , 1997, Obstetrics and gynecology.

[12]  R. Perry,et al.  Yersinia pestis--etiologic agent of plague , 1997, Clinical microbiology reviews.

[13]  David R Franz,et al.  Medical Aspects of Chemical and Biological Warfare , 1997 .

[14]  J. Frean,et al.  In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from a southern African plague focus , 1996, Antimicrobial agents and chemotherapy.

[15]  T. Quan,et al.  Identification of Yersinia pestis by BBL Crystal Enteric/Nonfermenter Identification System , 1996, Journal of clinical microbiology.

[16]  R. Titball,et al.  Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice. , 1996, The Journal of antimicrobial chemotherapy.

[17]  S. Welkos,et al.  Pathology of experimental pneumonic plague produced by fraction 1-positive and fraction 1-negative Yersinia pestis in African green monkeys (Cercopithecus aethiops). , 1996, Archives of pathology & laboratory medicine.

[18]  J. Garner.  Guideline for isolation precautions in hospitals. Part II. Recommendations for isolation precautions in hospitals. Hospital Infection Control Practices Advisory Committee. , 1996, American journal of infection control.

[19]  A D Coox,et al.  Factories of death. , 1995, Science.

[20]  J. Wain,et al.  In vitro antimicrobial susceptibilities of strains of Yersinia pestis , 1995, Antimicrobial agents and chemotherapy.

[21]  G. McEvoy,et al.  AHFS Drug Information , 1994 .

[22]  I. Kasatkina,et al.  [Virulence of rifampicin and quinolone resistant mutants of strains of plague microbe with Fra+ and Fra- phenotypes]. , 1994, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic].

[23]  J. Amouroux,et al.  Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection , 1994, Antimicrobial Agents and Chemotherapy.

[24]  S. Morse,et al.  [1] Recommendations for working with pathogenic bacteria , 1994 .

[25]  Ryzhkova Vv,et al.  Effectiveness of doxycycline in experimental plague , 1993 .

[26]  P. Brachman,et al.  Bacterial infections of humans: epidemiology and control. , 1993 .

[27]  I. Kasatkina,et al.  [Doxycycline in the prevention of experimental plague induced by plague microbe variants]. , 1992, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic].

[28]  E. Lyamuya,et al.  Laboratory studies on Yersinia pestis during the 1991 outbreak of plague in Lushoto, Tanzania. , 1992, The Journal of tropical medicine and hygiene.

[29]  L D Crook,et al.  Plague. A clinical review of 27 cases. , 1992, Archives of internal medicine.

[30]  T. Butler.  The black death past and present. 1. Plague in the 1980s. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[31]  E. Chernin.  Richard Pearson Strong and the Manchurian epidemic of pneumonic plague, 1910-1911. , 1989, Journal of the history of medicine and allied sciences.

[32]  K. Watterberg,et al.  The need for a loading dose of gentamicin in neonates. , 1989 .

[33]  B. Rasoamanana,et al.  [Sensitivity of Yersinia pestis to antibiotics: 277 strains isolated in Madagascar between 1926 and 1989]. , 1989, Archives de l'Institut Pasteur de Madagascar.

[34]  T. Wong.  Plague in a Pregnant Patient , 1986, Tropical doctor.

[35]  E. Kompare,et al.  Nineteen cases of plague in Arizona. A spectrum including ecthyma gangrenosum due to plague and plague in pregnancy. , 1985, The Western journal of medicine.

[36]  B. C. Nelson,et al.  Primary plague pneumonia contracted from a domestic cat at South Lake Tahoe, Calif. , 1984, JAMA.

[37]  T. Butler.  Plague and Other Yersinia Infections , 1983, Current Topics in Infectious Disease.

[38]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .

[39]  Lewiecki Em.  Primary plague septicemia. Case report. , 1978 .

[40]  E. Lewiecki.  Primary plague septicemia. Case report. , 1978, Rocky Mountain medical journal.

[41]  T. Butler,et al.  Yersinia pestis infection in Vietnam. II. Quantiative blood cultures and detection of endotoxin in the cerebrospinal fluid of patients with meningitis. , 1976, The Journal of infectious diseases.

[42]  T. Butler,et al.  Yersinia pestis infection in Vietnam. I. Clinical and hematologic aspects. , 1974, The Journal of infectious diseases.

[43]  E. Montaña.  Project DDD , 1973 .

[44]  F. Burkle.  Plague as seen in South Vietnamese children. A chronicle of observations and treatment under adverse conditions. , 1973, Clinical pediatrics.

[45]  F. Burkle.  Plague As Seen in South Vietnamese Children , 1973 .

[46]  M. Finegold,et al.  Studies on the pathogenesis of plague. Blood coagulation and tissue responses of Macaca mulatta following exposure to aerosols of Pasteurella pestis. , 1968, The American journal of pathology.

[47]  J. L. Scott,et al.  A CONTROLLED DOUBLE-BLIND STUDY OF THE HEMATOLOGIC TOXICITY OF CHLORAMPHENICOL. , 1965, The New England journal of medicine.

[48]  W. D. Tigertt,et al.  Laboratory-acquired pneumonic plague. Report of a case and review of previous cases. , 1962, Annals of internal medicine.

[49]  K. Meyer.  PNEUMONIC PLAGUE , 1927, Bacteriological reviews.

[50]  R. Speck,et al.  Studies on the experimental epidemiology of respiratory infections. VIII. Experimental pneumonic plague in Macacus rhesus. , 1957, The Journal of infectious diseases.

[51]  J. Robic,et al.  Chloramphenicol and terramycin in the treatment of pneumonic plague. , 1953, The American journal of medicine.

[52]  B LOGAN,et al.  Obstetrics and Gynecology , 1917, Edinburgh Medical Journal.

[53]  W. Lien-teh,et al.  A Treatise on Pneumonic Plague. , 1926 .

[54]  W. H. Kellogg.  AN EPIDEMIC OF PNEUMONIC PLAGUE. , 1920, American journal of public health.